Cart
sales@molnova.com
Cimigenoside
CAS No. 27994-11-2
Cimigenoside( —— )
Catalog No. M18356 CAS No. 27994-11-2
Cimigenoside is an active compound from genus Cimicifuga.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 103 | In Stock |
|
| 5MG | 67 | In Stock |
|
| 10MG | 96 | In Stock |
|
| 25MG | 162 | In Stock |
|
| 50MG | 233 | In Stock |
|
| 100MG | 347 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCimigenoside
-
NoteResearch use only, not for human use.
-
Brief DescriptionCimigenoside is an active compound from genus Cimicifuga.
-
DescriptionCimigenoside is an active compound from genus Cimicifuga.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number27994-11-2
-
Formula Weight620.82
-
Molecular FormulaC35H56O9
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (161.08 mM)
-
SMILESCC1CC2C(OC3(C1C4(CCC56CC57CCC(C(C7CCC6C4(C3O)C)(C)C)OC8C(C(C(CO8)O)O)O)C)O2)C(C)(C)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Selatinib
Selatinib is an orally active and potent dual inhibitor of EGFR and ErbB2 with anticancer activity that inhibits the growth of NCI-N87 tumor cells.
-
Nimotuzumab
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
-
EGFR-IN-8
EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC. EGFR-IN-8 is a dual EGFR and c-Met inhibitor.
